Proteomics profiling reveals inflammatory biomarkers of antidepressant treatment response: Findings from the CO-MED trial

Journal of Psychiatric Research

Volumn 94, Issue , 2017, Pages 1-6

  Gadad, Bharathi S ^a   Jha, Manish K ^a   Grannemann, Bruce D ^a   Mayes, Taryn L ^a   Trivedi, Madhukar H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Antidepressant; Cytokine; Eotaxin 1 CCL11; IFN ; Multiplex; Predictor

Indexed keywords

AMFEBUTAMONE; AMYLOID P COMPONENT; BIOLOGICAL MARKER; EOTAXIN; ESCITALOPRAM; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 5; MIRTAZAPINE; PLACEBO; RANTES; VENLAFAXINE; ANTIDEPRESSANT AGENT; CCL11 PROTEIN, HUMAN; CYTOKINE; PROTEOME; SERUM AMYLOID P;

ADD ON THERAPY; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL OUTCOME; CONTROLLED STUDY; DEPRESSION; DRUG DOSE INCREASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL; REMISSION; SINGLE BLIND PROCEDURE; STANDARD; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; DRUG EFFECT; IMMUNOLOGY; INFLAMMATION; MAJOR DEPRESSION; MIDDLE AGED; PROCEDURES;

ADULT; ANTIDEPRESSIVE AGENTS; BIOMARKERS; CHEMOKINE CCL11; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; INFLAMMATION; INTERFERON-GAMMA; MALE; MIDDLE AGED; PROTEOME; PROTEOMICS; REMISSION INDUCTION; SERUM AMYLOID P-COMPONENT; SINGLE-BLIND METHOD;

EID: 85020913161     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2017.05.012     Document Type: Article

References (31)

1. Akhondzadeh, S., Jafari, S., Raisi, F., Nasehi, A.A., Ghoreishi, A., Salehi, B., Mohebbi-Rasa, S., Raznahan, M., Kamalipour, A., Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 26:7 (2009), 607–611.
2. Bot, M., Chan, M.K., Jansen, R., Lamers, F., Vogelzangs, N., Steiner, J., Leweke, F.M., Rothermundt, M., Cooper, J., Bahn, S., Penninx, B.W., Serum proteomic profiling of major depressive disorder. Transl. Psychiatry, 5, 2015, e599.
3. Brunoni, A.R., Machado-Vieira, R., Zarate, C.A., Valiengo, L., Vieira, E.L., Bensenor, I.M., Lotufo, P.A., Gattaz, W.F., Teixeira, A.L., Cytokines plasma levels during antidepressant treatment with sertraline and transcranial direct current stimulation (tDCS): results from a factorial, randomized, controlled trial. Psychopharmacol. Berl. 231:7 (2014), 1315–1323.
4. Dantzer, R., O'Connor, J.C., Freund, G.G., Johnson, R.W., Kelley, K.W., From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9:1 (2008), 46–56.
5. Diamond, M., Kelly, J.P., Connor, T.J., Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur. Neuropsychopharmacol. 16:7 (2006), 481–490.
6. Felger, J.C., Lotrich, F.E., Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 246 (2013), 199–229.
7. Fredriksson, K., Fielhaber, J.A., Lam, J.K., Yao, X., Meyer, K.S., Keeran, K.J., Zywicke, G.J., Qu, X., Yu, Z.X., Moss, J., Kristof, A.S., Levine, S.J., Paradoxical effects of rapamycin on experimental house dust mite-induced asthma. PloS one, 7(5), 2012, e33984.
8. Grassi-Oliveira, R., Brieztke, E., Teixeira, A., Pezzi, J.C., Zanini, M., Lopes, R.P., Bauer, M.E., Peripheral chemokine levels in women with recurrent major depression with suicidal ideation. Rev. Bras. Psiquiatr. 34:1 (2012), 71–75.
9. Hauser, P., Khosla, J., Aurora, H., Laurin, J., Kling, M.A., Hill, J., Gulati, M., Thornton, A.J., Schultz, R.L., Valentine, A.D., Meyers, C.A., Howell, C.D., A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol. Psychiatry 7:9 (2002), 942–947.
10. Himmerich, H., Fulda, S., Sheldrick, A.J., Plumakers, B., Rink, L., IFN-gamma reduction by tricyclic antidepressants. Int. J. Psychiatry Med. 40:4 (2010), 413–424.
11. Himmerich, H., Milenovic, S., Fulda, S., Plumakers, B., Sheldrick, A.J., Michel, T.M., Kircher, T., Rink, L., Regulatory T cells increased while IL-1beta decreased during antidepressant therapy. J. Psychiatr. Res. 44:15 (2010), 1052–1057.
12. Jha, M.K., Minhajuddin, A., Gadad, B.S., Greer, T., Grannemann, B., Soyombo, A., Mayes, T.L., Rush, A.J., Trivedi, M.H., Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. Psychoneuroendocrinology 78 (2017), 105–113.
13. Kenis, G., Maes, M., Effects of antidepressants on the production of cytokines. Int. J. Neuropsychopharmacol. 5:4 (2002), 401–412.
14. Li, N., Lee, B., Liu, R.J., Banasr, M., Dwyer, J.M., Iwata, M., Li, X.Y., Aghajanian, G., Duman, R.S., mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329:5994 (2010), 959–964.
15. Maes, M., Evidence for an immune response in major depression: a review and hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatry 19:1 (1995), 11–38.
16. Maes, M., Song, C., Lin, A.H., Bonaccorso, S., Kenis, G., De Jongh, R., Bosmans, E., Scharpe, S., Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology 20:4 (1999), 370–379.
17. Magalhaes, P.V., Jansen, K., Stertz, L., Ferrari, P., Pinheiro, R.T., da Silva, R.A., Kapczinski, F., Peripheral eotaxin-1 (CCL11) levels and mood disorder diagnosis in a population-based sample of young adults. J. Psychiatr. Res. 48:1 (2014), 13–15.
18. Melik-Parsadaniantz, S., Rostene, W., Chemokines and neuromodulation. J. Neuroimmunol. 198:1–2 (2008), 62–68.
19. Munzer, A., Sack, U., Mergl, R., Schonherr, J., Petersein, C., Bartsch, S., Kirkby, K.C., Bauer, K., Himmerich, H., Impact of antidepressants on cytokine production of depressed patients in vitro. Toxins (Basel) 5:11 (2013), 2227–2240.
20. Mushaben, E.M., Kramer, E.L., Brandt, E.B., Khurana Hershey, G.K., Le Cras, T.D., Rapamycin attenuates airway hyperreactivity, goblet cells, and IgE in experimental allergic asthma. J. Immunol. 187:11 (2011), 5756–5763.
21. Myung, W., Lim, S.W., Woo, H.I., Park, J.H., Shim, S., Lee, S.Y., Kim, D.K., Serum cytokine levels in major depressive disorder and its role in antidepressant response. Psychiatry Investig. 13:6 (2016), 644–651.
22. Rothman, K.J., No adjustments are needed for multiple comparisons. Epidemiology 1:1 (1990), 43–46.
23. Rush, A.J., Trivedi, M.H., Ibrahim, H.M., Carmody, T.J., Arnow, B., Klein, D.N., Markowitz, J.C., Ninan, P.T., Kornstein, S., Manber, R., Thase, M.E., Kocsis, J.H., Keller, M.B., The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol. Psychiatry 54:5 (2003), 573–583.
24. Rush, A.J., Trivedi, M.H., Stewart, J.W., Nierenberg, A.A., Fava, M., Kurian, B.T., Warden, D., Morris, D.W., Luther, J.F., Husain, M.M., Cook, I.A., Shelton, R.C., Lesser, I.M., Kornstein, S.G., Wisniewski, S.R., Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am. J. Psychiatry 168:7 (2011), 689–701.
25. Saville, D.J., Multiple comparison procedures - the practical solution. Am. Stat. 44:2 (1990), 174–180.
26. Schmidt, F.M., Schroder, T., Kirkby, K.C., Sander, C., Suslow, T., Holdt, L.M., Teupser, D., Hegerl, U., Himmerich, H., Pro- and anti-inflammatory cytokines, but not CRP, are inversely correlated with severity and symptoms of major depression. Psychiatry Res. 239 (2016), 85–91.
27. Stelzhammer, V., Haenisch, F., Chan, M.K., Cooper, J.D., Steiner, J., Steeb, H., Martins-de-Souza, D., Rahmoune, H., Guest, P.C., Bahn, S., Proteomic changes in serum of first onset, antidepressant drug-naive major depression patients. Int. J. Neuropsychopharmacol. 17:10 (2014), 1599–1608.
28. Strasser, B., Becker, K., Fuchs, D., Gostner, J.M., Kynurenine pathway metabolism and immune activation: peripheral measurements in psychiatric and co-morbid conditions. Neuropharmacology 112:Pt B (2017), 286–296.
29. Trivedi, M.H., Rush, A.J., Ibrahim, H.M., Carmody, T.J., Biggs, M.M., Suppes, T., Crismon, M.L., Shores-Wilson, K., Toprac, M.G., Dennehy, E.B., Witte, B., Kashner, T.M., The inventory of depressive Symptomatology, clinician rating (IDS-C) and self-report (IDS-SR), and the Quick inventory of depressive Symptomatology, clinician rating (QIDS-C) and self-report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol. Med. 34:1 (2004), 73–82.
30. Trivedi, M.H., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Warden, D., Ritz, L., Norquist, G., Howland, R.H., Lebowitz, B., McGrath, P.J., Shores-Wilson, K., Biggs, M.M., Balasubramani, G.K., Fava, M., Team, S.D.S., Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163:1 (2006), 28–40.
31. Uher, R., Tansey, K.E., Dew, T., Maier, W., Mors, O., Hauser, J., Dernovsek, M.Z., Henigsberg, N., Souery, D., Farmer, A., McGuffin, P., An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am. J. Psychiatry 171:12 (2014), 1278–1286.